Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Neovacs S.A.. (5/17/16). "Press Release: Neovacs to Attend ChinaBio Event. May 18 & 19, 2016". Paris & Boston, MA.

Organisations Organisation Neovacs S.A. (Euronext Growth Paris: ALNEV)
  Group Neovacs (Group)
  Organisation 2 Stellar Biotechnologies Inc. (Nasdaq: SBOT, TSX Venture: KLH)
Products Product ChinaBio Partnering Forum 2016 Suzhou
  Product 2 IFNalpha-Kinoid (IFNa-Kinoïd)
Index terms Index term Neovacs–Informa: partnering conference, 201605 supply service Neovacs participates in ChinaBio Partnering Forum 2016 in Suzhou
  Index term 2 Chong Kun Dang–Neovacs: IFNalpha Kinoid, 201512– license excl for ROK + supply €1m upfront + €4m milestones + royalties + margin on supply
Persons Person Masson, Charlène (Neovacs 201601 Corp Communications + IR)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)

Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the ChinaBio® Partnering Forum, being held on May 18- 19 in Suzhou, China.

This forum is dedicated to biotechnology companies from around the world, enabling them to identify and meet local partners. Neovacs will have the opportunity to present its technology, strategy and recent news to prospective strategic partners in China, a region in which there are more than one million Lupus patients.

To further support its growth, Neovacs is seeking new partnerships. To achieve this goal, the company is in discussions with companies in five countries and over the past several months, has signed two new important development and commercialization partnerships with Chong Kun Dang Pharmaceutical Corp. in South Korea and Stellar Biotechnologies in the United States.

In April 2016, Neovacs obtained both authorization from the health authorities of South Korea and IND approval from the U.S. Food and Drug Administration (FDA) for its ongoing Phase IIb clinical trial with IFNa Kinoid to treat Lupus.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.


NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14

Investor Relations / Financial Communications Germany – MC Services
Raimund Gabriel

Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013 /

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Neovacs (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top